Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?
- PMID: 29907623
- DOI: 10.1158/1078-0432.CCR-18-1475
Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?
Abstract
Immunosenescence might be expected to reduce the efficacy of checkpoint blockade, which depends on a functionally intact immune system. However, it seems that older patients with melanoma may respond better to anti-PD-1 treatment than younger patients, possibly due to their having fewer regulatory T cells relative to CD8+ T cells within tumor deposits. Clin Cancer Res; 24(21); 5193-4. ©2018 AACR See related article by Kugel et al., p. 5347.
©2018 American Association for Cancer Research.
Comment on
-
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.Clin Cancer Res. 2018 Nov 1;24(21):5347-5356. doi: 10.1158/1078-0432.CCR-18-1116. Epub 2018 Jun 13. Clin Cancer Res. 2018. PMID: 29898988 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials